Jens Kristensen
Overview
Explore the profile of Jens Kristensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
854
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moradi R, Kristensen J, Logstrup B
HeartRhythm Case Rep
. 2025 Feb;
10(12):903-906.
PMID: 39897671
No abstract available.
2.
Zhang H, Lafayette R, Wang B, Ying L, Zhu Z, Stone A, et al.
Kidney360
. 2024 Dec;
5(12):1881-1892.
PMID: 39724565
Background: IgA nephropathy (IgAN), an immune-mediated kidney disease, is particularly prevalent among individuals of East Asian ancestry. Nefecon is a novel, oral, targeted-release budesonide formulation designed to inhibit galactose-deficient IgA1...
3.
Zaman J, Khan A, Nielsen J, Kristiansen S, Kronborg M, Witt C, et al.
Heart Rhythm O2
. 2024 Sep;
5(8):543-550.
PMID: 39263613
Background: Electrogram dispersion identifies putative atrial fibrillation (AF) drivers in first time ablation procedures, with high acute termination rates and long-term outcomes akin to extensive ablation approaches. Its use in...
4.
Barratt J, Kristensen J, Pedersen C, Jerling M
Drug Des Devel Ther
. 2024 Aug;
18:3415-3428.
PMID: 39100224
Immunoglobulin A nephropathy (IgAN) is a chronic, immune-mediated kidney disease characterized by the deposition of galactose-deficient immunoglobulin A1 (Gd-IgA1) in the kidneys. Excess Gd-IgA1 production in patients with IgAN is...
5.
Lafayette R, Kristensen J, Stone A, Barratt J
Lancet
. 2024 Jun;
403(10446):2786.
PMID: 38944527
No abstract available.
6.
Kronborg M, Frausing M, Malczynski J, Riahi S, Haarbo J, Holm K, et al.
Eur Heart J
. 2023 Aug;
44(40):4246-4255.
PMID: 37638973
Background And Aims: High percentages of atrial pacing have been associated with an increased risk of atrial fibrillation. This study is aimed at evaluating whether atrial pacing minimization in patients...
7.
Lafayette R, Kristensen J, Stone A, Floege J, Tesar V, Trimarchi H, et al.
Lancet
. 2023 Aug;
402(10405):859-870.
PMID: 37591292
Background: IgA nephropathy is a chronic immune-mediated kidney disease and a major cause of kidney failure worldwide. The gut mucosal immune system is implicated in its pathogenesis, and Nefecon is...
8.
Jespersen C, Kroll J, Bhardwaj P, Winkel B, Jacobsen P, Jons C, et al.
Europace
. 2023 May;
25(5).
PMID: 37129985
Aims: Reduced psychological health is associated with adverse patient outcomes and higher mortality. We aimed to examine if a Brugada syndrome (BrS) diagnosis and symptomatic disease presentation were associated with...
9.
Frausing M, Baek A, Kristensen J, Gerdes C, Nielsen J, Kronborg M
J Interv Card Electrophysiol
. 2023 Feb;
66(8):1849-1857.
PMID: 36753028
Background: His bundle pacing (HBP) is a novel treatment with limited knowledge on long-term outcome. We aimed to assess long-term safety and effectiveness of HBP in patients with atrioventricular block...
10.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, et al.
Kidney Int
. 2022 Oct;
103(2):391-402.
PMID: 36270561
The therapeutic potential of a novel, targeted-release formulation of oral budesonide (Nefecon) for the treatment of IgA nephropathy (IgAN) was first demonstrated by the phase 2b NEFIGAN trial. To verify...